Literature DB >> 8553950

Dynamic MR imaging and early-phase helical CT for detecting small intrahepatic metastases of hepatocellular carcinoma.

H Oi1, T Murakami, T Kim, M Matsushita, H Kishimoto, H Nakamura.   

Abstract

OBJECTIVE: We performed a study to evaluate the sensitivities of multislice dynamic MR imaging and early-phase helical CT as noninvasive methods for detecting small intrahepatic metastases of hepatocellular carcinomas.
MATERIALS AND METHODS: Dynamic and spin-echo MR imaging and early- and delayed-phase helical CT of the liver were performed for patients with multiple hepatocellular carcinomas before transcatheter arterial chemoembolization. Forty-nine patients had 242 intrahepatic metastases less than 3 cm in diameter. Using iodized-oil CT after transcatheter arterial chemoembolization as a gold standard, the sensitivity of MR imaging for detecting intrahepatic metastases was compared with that of CT.
RESULTS: Of the 242 nodules, 225 were diagnosed as hepatocellular carcinomas by iodized-oil CT. Of these, dynamic MR imaging and early-phase CT were significantly superior to those of spin-echo MR imaging (p < .0001) and delayed phase CT (p < .0001) for tumors less than 1 cm in diameter.
CONCLUSION: Dynamic MR imaging and early-phase CT of the liver are the most sensitive noninvasive means of detecting small intrahepatic metastases of hepatocellular carcinoma before and after treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8553950     DOI: 10.2214/ajr.166.2.8553950

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  10 in total

1.  Value of lipiodol computed tomography and digital subtraction angiography in the era of helical biphasic computed tomography as preoperative assessment of hepatocellular carcinoma.

Authors:  A Nakayama; H Imamura; Y Matsuyama; H Kitamura; S Miwa; A Kobayashi; S Miyagawa ; S Kawasaki
Journal:  Ann Surg       Date:  2001-07       Impact factor: 12.969

2.  Controversies in imaging of hepatocellular carcinoma: multidetector CT (MDCT).

Authors:  Paul M Silverman; Janio Szklaruk
Journal:  Cancer Imaging       Date:  2005-12-10       Impact factor: 3.909

Review 3.  [Diagnostic radiology of liver tumors. Part 1: General disease aspects and radiological procedures].

Authors:  G Layer; M Bohrer
Journal:  Radiologe       Date:  2007-09       Impact factor: 0.635

Review 4.  Magnetic resonance imaging of the cirrhotic liver: An update.

Authors:  Agnes Watanabe; Miguel Ramalho; Mamdoh AlObaidy; Hye Jin Kim; Fernanda G Velloni; Richard C Semelka
Journal:  World J Hepatol       Date:  2015-03-27

5.  Diagnostic performance of MDCT, PET/CT and gadoxetic acid (Primovist(®))-enhanced MRI in patients with colorectal liver metastases being considered for hepatic resection: initial experience in a single centre.

Authors:  V O Chan; J P Das; J F Gerstenmaier; J Geoghegan; R G Gibney; C D Collins; S J Skehan; D E Malone
Journal:  Ir J Med Sci       Date:  2012-03-17       Impact factor: 1.568

6.  Role and limitation of FMPSPGR dynamic contrast scanning in the follow-up of patients with hepatocellular carcinoma treated by TACE.

Authors:  Fu-Hua Yan; Kang-Rong Zhou; Jie-Min Cheng; Jian-Hua Wang; Zhi-Ping Yan; Reng-Rong Da; Jia Fan; Yuan Ji
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

7.  Ablation of large HCCs using a new saline-enhanced expandable radiofrequency device().

Authors:  L Tarantino; I Sordelli; V Nocera; A Piscopo; C Ripa; D Parmeggiani; P Sperlongano
Journal:  J Ultrasound       Date:  2009-04-02

8.  MRI in detection of hepatocellular carcinoma (HCC).

Authors:  Subba R Digumarthy; Dushyant V Sahani; Sanjay Saini
Journal:  Cancer Imaging       Date:  2005-04-13       Impact factor: 3.909

Review 9.  New MR techniques for the detection of liver metastases.

Authors:  J Ward
Journal:  Cancer Imaging       Date:  2006-05-31       Impact factor: 3.909

10.  Hepatocellular carcinoma - issues in imaging.

Authors:  C H Thng; Y T Kuo
Journal:  Cancer Imaging       Date:  2004-10-20       Impact factor: 3.909

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.